Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor"associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Frequently asked questions
What sector does Odyssey Therapeutics, Inc. Common Stock (ODTX) operate in?
Odyssey Therapeutics, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Odyssey Therapeutics, Inc. Common Stock (ODTX) current stock price?
As of the latest data, Odyssey Therapeutics, Inc. Common Stock stock price is $19.30, with a previous close of $19.60. Odyssey Therapeutics, Inc. Common Stock lost -$0.30 in the last trading session, representing a -1.53% loss.
What is Odyssey Therapeutics, Inc. Common Stock (ODTX) current market capitalization?
Odyssey Therapeutics, Inc. Common Stock market cap is approximately 927.53 million.
What is Odyssey Therapeutics, Inc. Common Stock (ODTX) Earnings Per Share (EPS)?
The trailing EPS is -$3.34, and the forward EPS is -$4.36.
What is Odyssey Therapeutics, Inc. Common Stock (ODTX) EBITDA?
Odyssey Therapeutics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -51.73 million.
Does Odyssey Therapeutics, Inc. Common Stock (ODTX) pay dividends?
No. Odyssey Therapeutics, Inc. Common Stock does not pay a dividend.
When is Odyssey Therapeutics, Inc. Common Stock (ODTX) next earnings report?
Odyssey Therapeutics, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Odyssey Therapeutics, Inc. Common Stock (ODTX) beta (volatility) score?
Odyssey Therapeutics, Inc. Common Stock has a beta of 0.011, indicating lower volatility than the overall market.
